Durvalumab is primarily approved for the treatment of non-small cell lung cancer (NSCLC) and urothelial carcinoma, a type of bladder cancer. In NSCLC, it is used particularly in patients whose cancer has not progressed after platinum-based chemotherapy and radiation therapy. In the context of bladder cancer, durvalumab is used for patients with locally advanced or metastatic disease that have progressed during or after platinum-containing chemotherapy.
